Speciality Medicines Ltd. Share Price

Speciality Medicines

• Speciality Medicines is coming out with an initial public offering (IPO) of 23,50,000 shares in a price band of Rs 117-124 per equity share. 
• The issue will open on March 20, 2026 and will close on March 24, 2026.
• The shares will be listed on SME Platform of BSE.
• The face value of the share is Rs 10 and is priced 11.70 times of its face value on the lower side and 12.40 times on the higher side.
• Book running lead manager to the issue is Unistone Capital.
• Compliance Officer for the issue is Anita Kumawat.

Profile of the company

The company is engaged in the business of marketing and distribution of finished formulations of specialty pharmaceutical products, comprising of high-cost oral and injectable medications used in the treatment of complex and chronic medical conditions in therapeutic areas like oncology, immunology, neurology and rare diseases. It offers a diverse portfolio of specialty pharmaceutical products, focusing on various therapeutic areas such as oncology, immunology, neurology, and rare diseases. Its products which are offered in such areas are available in a wide range of dosage forms like Tablets, Capsules, Cream, Syrups, Eye Drops, Gel, Infusion, Inhalation, Inhaler, Injection, Nasal Spray, Ointment, Ophthalmic, Oral Solution, Oral Suspension, Sachet and Suspension. It operates through two integrated business models: i) Manufacturing, through contract manufacturing basis, of approved finished formulations and distribution internationally and ii) Marketing and distribution of specialty pharmaceutical products sourced from manufacturers. 

Under its contract manufacturing arrangement, its contract manufacturer based in India is responsible for the manufacturing of speciality pharmaceutical formulations. These formulations are either approved or currently undergoing the approval process with the relevant health authorities in the target countries. Once the necessary regulatory approvals are obtained, it initiates its role as the distributor for these products. Its responsibilities include overseeing the marketing and distribution of the approved specialty pharmaceutical products across multiple international markets. Under its other business model, it operates as a distributor of specialty pharmaceutical products sourced from manufacturers. Its role focuses on the procurement, warehousing, and wholesale distribution of these medicines to a wide network of healthcare providers and retailers. It ensures smooth supply chain operations and timely delivery across various regions. Its services are centred on maintaining consistent product availability and supporting its customers through reliable and efficient distribution. 

Through this dual-model approach, the company effectively distributes and markets specialty pharmaceutical products across India and overseas, maintaining a strong focus on quality and regulatory compliance. It has established its presence in international markets through products that are either registered or in the process of registration in countries which includes Jordan, Ethiopia, Uganda, Peru and Namibia. It has, through its distributions, established good relationship with its customers spreading across more than 20 states of India and more than 35 countries all over the world. 

Proceed is being used for:

• Setting up of Research and Development (R&D) Centre in Gujarat
• Product registration in international markets and product development for sale in international markets.
• Funding for marketing and promotional activities
• Meeting working capital requirements
• General corporate purpose.

Industry Overview

India’s pharmaceutical industry is one of the most significant contributors to the national economy and a key player in the global healthcare landscape. The country ranks third globally in pharmaceutical production by volume and 14th by value and is widely recognized as the ‘Pharmacy of the World’ owing to its large-scale production and export of affordable, high-quality generic medicines and vaccines. India is the largest provider of generic drugs globally, accounting for around 20% of the global supply by volume and contributes over 60% of the global vaccine demand. As of 2024, India is home to over 3,000 pharmaceutical companies and more than 10,000 manufacturing facilities, including the highest number of USFDA-compliant plants outside the United States. This has positioned the country as a critical part of the global pharmaceutical supply chain, especially for regulated markets such as the United States, European Union, and Japan. The Indian pharmaceutical sector is evolving from a volume-driven industry to a value-based, innovation-led sector. There is a rising focus on complex generics, specialty drugs, biosimilars, and novel drug delivery systems, particularly in therapeutic areas such as oncology, cardiology, anti-diabetics, and central nervous system (CNS) disorders. Increasing investments in research and development (R&D), combined with strategic global partnerships and acquisitions, are enabling Indian pharmaceutical companies to enter higher-margin and technologically intensive product segments.

The Indian pharmaceutical industry offers a broad and diversified production mix across multiple therapeutic categories, catering to both domestic consumption and export markets. The production pattern in FY25 indicates a strong emphasis on traditional medicine, infectious disease treatment, and chronic condition management, showcasing the industry’s evolving response to healthcare needs. Ayurvedic and Homeopathic Medicaments constituted the largest share of production at 24.8%, highlighting the rising consumer preference for traditional healthcare solutions and continued government support for AYUSH-based formulations. Antibiotics, API & Formulations represented 18.8% of total production, reinforcing India’s role as a major global supplier of critical antimicrobial agents. Anti-retroviral Drugs for HIV Treatment accounted for 14.0%, underlining India’s contribution to affordable therapies for communicable diseases, particularly for developing countries. Anti-pyretic, Analgesic and Anti-inflammatory APIs & Formulations contributed 8.1%, reflecting widespread demand for pain and fever management therapies. Capsules accounted for 6.1%, showcasing the demand for flexible and efficient oral dosage forms. Vaccines for Veterinary Medicine contributed 5.3%, pointing toward a growing emphasis on animal health and veterinary pharmaceutical production. Antidiabetic Drugs (4.7%), API & Formulations of Vitamins (4.3%), and Medical/Surgical Accessories (3.6%) indicate increased demand driven by lifestyle-related health conditions and improvements in healthcare infrastructure. Other significant categories include Steroids and Hormonal Preparations (including anti-fungal) at 3.7%, IV Fluids at 1.5%, and Anti-cancer Drugs for Chemotherapy at 1.2%. Smaller production volumes are observed in niche therapeutic segments such as Anti-psychotic Drugs (0.5%), Antituberculosis Medicines (0.4%), Antiseptics and Disinfectants (0.9%), and API for Lipid-Lowering Agents (0.1%), indicating selective or demand-driven manufacturing in these areas.

The Indian pharmaceutical industry is poised for significant growth in the coming years, driven by several key factors. The Indian pharmaceutical industry is estimated to reach $53.78 billion in FY 2025. Looking ahead, the industry is projected to grow at a Compounded Annual Growth Rate (CAGR) of 9.53%, reaching a market size of $58.90 in FY 2026 and $84.77 billion by 2030. The sector has demonstrated consistent growth, driven by increasing healthcare expenditure, expansion of insurance coverage, a rising burden of chronic and lifestyle diseases, and the growing penetration of specialty and high-value therapies. The government’s support through initiatives like the Production-Linked Incentive (PLI) scheme has been instrumental in enhancing domestic manufacturing capabilities. In the fiscal year 2024-25, the pharmaceutical sector received around 70% of the total incentive disbursements under the PLI schemes, highlighting the government’s focus on boosting domestic manufacturing in this key industry. Technological advancements are also playing a crucial role. The integration of artificial intelligence (AI) in drug discovery and development is enabling more personalized and efficient healthcare solutions. Furthermore, the commercialization of weight-loss drugs and the increasing demand for oncology treatments are opening new market avenues.

Pros and strengths

Diversified global presence: Its business is diversified in terms of geographies within the pharmaceutical industry. It has established its presence in both India and international markets, including countries like Bolivia, Cambodia, Italy, Latvia, Lithuania, Poland, Georgia, United Kingdom, Guyana, Brazil, Trinidad & Tobago, Armenia, Saudi Arabia, Belarus, UAE, Jordan, Oman, Kuwait, Bahrain, Turkey, DR Congo, Mali, Senegal, Uganda, Bangladesh, Malaysia, Philippines, Singapore, Vietnam, Thailand, Fiji, Japan, Ghana, Kenya, Myanmar, and Peru. It is actively focusing on adding more international markets to its portfolio. This diversified revenue base enables it to mitigate the risk of income concentration by spreading revenue across multiple sources, thereby opening new opportunities for growth.

Quality assurance: The quality is an ongoing process of sustaining existing and developing new relationships. It has obtained ISO 9001:2015 Certification for its Quality Management System from QVA Certification, SW Washington, D.C. 20202. Additionally, it ensures that its third-party manufacturing facilities are accredited with the necessary accreditation and provide quality output for its customers. It sets very high standards for itself regarding the timelines and quality of service it provides to its customers. Its stringent systems ensure that all products reach its customers on time and with minimal errors, reduce product rejection. Its commitment to quality service has earned it goodwill from its customers, resulting in customer retention and repeated orders. It has also helped it expand its customer base. It has developed internal procedures for checking client orders at each stage, from customer order to delivery. The company focuses on maintaining consistency in its services, thereby building customer loyalty for its brand.

Diversified product portfolio: Its product portfolio is diversified within the pharmaceutical sector, encompassing a broad range of therapeutic segments and dosage forms. It offers formulations across therapeutic categories such as anti-infectives, gastroenterology, cardiology, diabetology, dermatology, gynaecology, neurology, etc. Its offerings include tablets, capsules, liquids, injectables, ointments, creams, and sachets, catering to a wide variety of patient needs. This diversity allows it to serve a broad customer base and respond effectively to evolving market demands. A balanced product mix not only strengthens its market presence but also reduces dependency on any single therapeutic area, ensuring sustainable growth and stability in its revenues.

Risks and concerns

Revenue concentration risks from top customers: Reliance on a limited number of customers for its business may generally involve several risks. The company depends on top 10 customers for a significant portion of its revenues from operations which contributed 79.56%, 74.90%, 61.36% 70.86% of its revenue from operations, respectively in a period ended October 31, 2025 and in the fiscal year 2025, 2024 and 2023. While it has developed relationships with certain of its customers, there can be no assurance that its significant customers in the past will continue to place orders or maintain the current level of business with it in the future. In order to retain some of its existing customers, it may also be required to offer terms to such customers which may place restraints on its resources. The loss of one or more of these significant customers or a significant decrease in business from any such key customer, whether due to circumstances specific to such customer or adverse market conditions affecting the pharmaceutical industry or the economic environment generally, may materially and adversely affect its business, results of operations and financial condition.

Risks associated with product development and expansion into new markets: One of the objectives of this issue is to get product development activities from third party service providers. This initiative is aimed at expanding its product portfolio, entering new therapeutic segments, and enhancing its market presence in both regulated and semi-regulated international geographies. The development of new products is subject to number of risks including, but not limited to, its failure to get developed products that meet market demands and market requirements, its failure to meet competition and its failure to comply with applicable regulations. In addition, its new products may require significant expenditure for development and roll out and may take substantial management time. Further, its investments in new products may be less profitable than what it has experienced historically or estimated, may be loss-making, may consume substantial financial resources and/or may divert management’s attention from existing operations, all of which could materially and adversely affect its business, results of operations and financial condition.

Supply chain risks and volatility in raw material prices: It relies on third-party suppliers for the raw materials required to produce its products from third party manufacturer. Since it does not have control over raw material costs, any increase in prices may not always be absorbed or passed on to customers. Such fluctuations can directly impact its margins, profitability, and overall business performance. The timely availability of good-quality raw materials with its suppliers at reasonable prices is critical for its operations. Any delay in sourcing, or a supplier’s inability to deliver materials on time, could disrupt production and deliveries, potentially leading to loss of customers and revenue.

Outlook

Speciality Medicines is engaged in the business of marketing and distribution of finished formulations of specialty pharmaceutical products, comprising of high-cost oral and injectable medications used in the treatment of complex and chronic medical conditions in therapeutic areas like oncology, immunology, neurology and rare diseases. It offers a diverse portfolio of specialty pharmaceutical products, focusing on various therapeutic areas such as oncology, immunology, neurology, and rare diseases. Its products which are offered in such areas are available in a wide range of dosage forms like Tablets, Capsules, Cream, Syrups, Eye Drops, Gel, Infusion, Inhalation, Inhaler, Injection, Nasal Spray, Ointment, Ophthalmic, Oral Solution, Oral Suspension, Sachet and Suspension. On the concern side, it has material exposure to foreign exchange related risks since a portion of its revenue from operations are in foreign currency, including the US Dollar. The exchange rate between the Indian Rupee and foreign currencies, primarily the USD, has fluctuated in the past and its results of operations have been impacted by such fluctuations in the past and may be impacted by such fluctuations in the future. Moreover, being a pharmaceutical company, it operates in a highly regulated and controlled industry environment. Its business is dependent on approvals from relevant regulatory and health authorities. Any delay or failure to obtain or renew such required regulatory approvals, registrations or any change in the regulatory environment in relation to marketing its products in regulated markets may significantly impact its business and strategy affecting its overall profitability.

The company is coming out with a maiden IPO of 23,50,000 equity shares of face value of Rs 10 each. The issue has been offered in a price band of Rs 117-124 per equity share. The aggregate size of the offer is around Rs 27.50 crore to Rs 29.14 crore based on lower and upper price band respectively. On performance front, the revenue from operations for FY25 stood at Rs 5,827.14 lakh whereas in FY24 it was Rs 2,752.48 lakh representing an increase of 111.71%. Moreover, profit after tax for the period ended March 31, 2025, stood at Rs 860.82 lakh and for the year ended March 31, 2024 it was Rs 293.36 lakh representing an increase of 193.43%.

The company plans to continue expanding its sales by registering additional new products in domestic and international markets. Its growth strategy will vary by country, depending on specific regulatory requirements. It may either form strategic partnerships with companies with a strong local presence or appoint local distributors for its sales and marketing efforts. Going forward, it plans to set up an R&D centre to transform from pure marketing organisation into an innovation driven speciality pharmaceutical company at Valsad, Gujarat. Further, it intends to invest in its in-house technical capabilities to develop customized systems and processes, ensuring effective management control over its critical resources for optimal utilization.

The Total revenue for the quarter ended March 2026 of  Rs. 107.63 millions grew by 177.11% from Rs. 38.84 millions.An average growth of 29.20% was recorded for the quarter ended March 2026 to Rs. 2.92  millions from Rs. 2.26 millions.The company reported a good operating profit of 3.22 millions compared to 2.26 millions of corresponding previous quarter.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202603	202503	% Var	202603	202503	% Var	202603	202503	% Var
Sales	107.63	38.84	177.11	193.38	38.84	397.89	193.38	38.84	397.89
Other Income	0.23	0.03	666.67	0.23	0.38	-39.47	0.23	0.38	-39.47
PBIDT	3.22	2.26	42.48	5.56	0.44	1163.64	5.56	0.44	1163.64
Interest	0.84	0.00	0.00	2.75	0.00	0.00	2.75	0.00	0.00
PBDT	2.21	2.26	-2.21	2.64	0.44	500.00	2.64	0.44	500.00
Depreciation	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
PBT	2.21	2.26	-2.21	2.64	0.44	500.00	2.64	0.44	500.00
TAX	-0.71	0.00	0.00	-0.71	0.00	0.00	-0.71	0.00	0.00
Deferred Tax	-0.77	0.00	0.00	-0.77	0.00	0.00	-0.77	0.00	0.00
PAT	2.92	2.26	29.20	3.35	0.44	661.36	3.35	0.44	661.36
Equity	100.00	31.52	217.26	100.00	31.52	217.26	100.00	31.52	217.26
PBIDTM(%)	2.99	5.82	-48.58	2.88	1.13	153.81	2.88	1.13	153.81

An increase of about 3440.23% to Rs. 92.40 millions in the total revenue was observed for the quarter ended March 2026. The total revenue was pegged at Rs. 2.61 millions during the similar quarter previous year.The Total Profit for the quarter ended March 2026 of Rs. 6.17 millions grew from Rs.-4.25 millions Operating profit Margin for the quarter ended March 2026 improved to 7.15% as compared to -2.30% of corresponding quarter ended March 2025

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202603	202503	% Var	202603	202503	% Var	202603	202503	% Var
Sales	92.40	2.61	3440.23	94.69	17.26	448.61	94.69	17.26	448.61
Other Income	1.20	3.02	-60.26	4.79	4.41	8.62	4.79	4.41	8.62
PBIDT	7.15	-2.30	-410.87	6.58	-5.69	-215.64	6.58	-5.69	-215.64
Interest	0.72	1.57	-54.14	2.17	1.58	37.34	2.17	1.58	37.34
PBDT	6.43	-3.87	-266.15	4.41	-7.27	-160.66	4.41	-7.27	-160.66
Depreciation	0.36	0.37	-2.70	1.44	1.46	-1.37	1.44	1.46	-1.37
PBT	6.07	-4.24	-243.16	2.97	-8.73	-134.02	2.97	-8.73	-134.02
TAX	-0.10	0.01	-1100.00	-0.02	0.02	-200.00	-0.02	0.02	-200.00
Deferred Tax	-0.10	0.01	-1100.00	-0.02	0.02	-200.00	-0.02	0.02	-200.00
PAT	6.17	-4.25	-245.18	2.99	-8.75	-134.17	2.99	-8.75	-134.17
Equity	108.00	108.00	0.00	108.00	108.00	0.00	108.00	108.00	0.00
PBIDTM(%)	7.74	-88.12	-108.78	6.95	-32.97	-121.08	6.95	-32.97	-121.08

The March 2026 quarter revenue stood at Rs. 213.57 millions, up 13.92% as compared to Rs. 187.48 millions during the corresponding quarter last year.The Net Loss for the quarter ended March 2026 is Rs. -56.15 millions as compared to Net Loss of Rs. -23.87 millions of corresponding quarter ended March 2025 Operating profit Margin for the quarter ended March 2026 further decreased to -60.42% as compared to -21.63% of corresponding quarter ended March 2025

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202603	202503	% Var	202603	202503	% Var	202603	202503	% Var
Sales	213.57	187.48	13.92	719.90	743.61	-3.19	719.90	743.61	-3.19
Other Income	-82.28	-37.96	116.75	40.94	97.18	-57.87	40.94	97.18	-57.87
PBIDT	-60.42	-21.63	179.33	93.17	151.71	-38.59	93.17	151.71	-38.59
Interest	0.39	0.28	39.29	1.42	1.40	1.43	1.42	1.40	1.43
PBDT	-60.81	-21.91	177.54	91.75	150.31	-38.96	91.75	150.31	-38.96
Depreciation	1.33	1.59	-16.35	5.42	6.24	-13.14	5.42	6.24	-13.14
PBT	-62.14	-23.50	164.43	86.33	144.07	-40.08	86.33	144.07	-40.08
TAX	-5.99	0.37	-1718.92	19.33	37.43	-48.36	19.33	37.43	-48.36
Deferred Tax	-13.09	-5.25	149.33	-12.85	16.71	-176.90	-12.85	16.71	-176.90
PAT	-56.15	-23.87	135.23	67.00	106.64	-37.17	67.00	106.64	-37.17
Equity	91.64	91.64	0.00	91.64	91.64	0.00	91.64	91.64	0.00
PBIDTM(%)	-28.29	-11.54	145.21	12.94	20.40	-36.56	12.94	20.40	-36.56

A slight decline in the revenue of Rs. 3085.10 millions was seen for the March 2026 quarter as against Rs. 3142.30 millions during year-ago period.Net profit surges 56.88% to Rs. 25.10  millions  from Rs. 16.00 millions in the quarter ended March 2026.The company reported a degrowth in operating Profit to 52.70 millions from 57.90 millions.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202603	202503	% Var	202603	202503	% Var	202603	202503	% Var
Sales	3085.10	3142.30	-1.82	14165.70	12742.60	11.17	14165.70	12742.60	11.17
Other Income	24.70	13.40	84.33	98.40	97.90	0.51	98.40	97.90	0.51
PBIDT	52.70	57.90	-8.98	289.80	256.70	12.89	289.80	256.70	12.89
Interest	15.80	32.60	-51.53	130.30	156.50	-16.74	130.30	156.50	-16.74
PBDT	36.90	25.30	45.85	159.50	100.20	59.18	159.50	100.20	59.18
Depreciation	1.80	1.80	0.00	6.90	4.70	46.81	6.90	4.70	46.81
PBT	35.10	23.50	49.36	152.60	95.50	59.79	152.60	95.50	59.79
TAX	10.00	7.50	33.33	39.60	25.60	54.69	39.60	25.60	54.69
Deferred Tax	-0.60	-0.30	100.00	-0.60	-0.30	100.00	-0.60	-0.30	100.00
PAT	25.10	16.00	56.88	113.00	69.90	61.66	113.00	69.90	61.66
Equity	569.10	569.10	0.00	569.10	569.10	0.00	569.10	569.10	0.00
PBIDTM(%)	1.71	1.84	-7.29	2.05	2.01	1.55	2.05	2.01	1.55